Opinion|Videos|July 22, 2024
Recent Data on Bimekizumab for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Sudden Death in HFpEF Often Preceded by Clinical Decline
3
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
4
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
5